Eisai Drug That Failed For Sepsis Could Be New Way To Treat Evolving Flu
This article was originally published in PharmAsia News
An Eisai drug that failed testing for treating another disease may be able to provide a new way of treating influenza, including the new viruses, by acting on the patient instead of the virus.
You may also be interested in...
Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.
New leaders in regulatory affairs and R&D at Skye Bioscience and promotions at Pieris Pharmaceuticals are among recent executive changes in the industry. Meanwhile, new directors were appointed at Summit Therapeutics, Ovid Therapeutics and Spero Therapeutics, among others.
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.